EA201170531A1 - Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака - Google Patents

Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака

Info

Publication number
EA201170531A1
EA201170531A1 EA201170531A EA201170531A EA201170531A1 EA 201170531 A1 EA201170531 A1 EA 201170531A1 EA 201170531 A EA201170531 A EA 201170531A EA 201170531 A EA201170531 A EA 201170531A EA 201170531 A1 EA201170531 A1 EA 201170531A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pyrimidine
pyridine
compounds based
cancer treatment
wnt signal
Prior art date
Application number
EA201170531A
Other languages
English (en)
Other versions
EA021828B1 (ru
Inventor
Эдвард Макдоналд
Джулиан Благг
Марк Пихович
Саймон Росс Крамплер
Original Assignee
Кэнсэр Ресерч Текнолоджи Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кэнсэр Ресерч Текнолоджи Лимитед filed Critical Кэнсэр Ресерч Текнолоджи Лимитед
Publication of EA201170531A1 publication Critical patent/EA201170531A1/ru
Publication of EA021828B1 publication Critical patent/EA021828B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

Настоящее изобретение относится к соединениям на основе пиридина и пиримидина, фармацевтическим композициям, включающим эти соединения, и их потенциальному применению в качестве терапевтических средств для лечения и/или профилактики рака.
EA201170531A 2008-10-06 2009-10-06 Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака EA021828B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0818241.2A GB0818241D0 (en) 2008-10-06 2008-10-06 Compounds and their use
PCT/GB2009/051319 WO2010041054A1 (en) 2008-10-06 2009-10-06 Pyridine and pyrimidine based compounds as wnt signaling pathway inhibitors for the treatment of cancer

Publications (2)

Publication Number Publication Date
EA201170531A1 true EA201170531A1 (ru) 2011-10-31
EA021828B1 EA021828B1 (ru) 2015-09-30

Family

ID=40042322

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201170531A EA021828B1 (ru) 2008-10-06 2009-10-06 Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака

Country Status (14)

Country Link
US (2) US8778925B2 (ru)
EP (1) EP2331523A1 (ru)
JP (1) JP5711129B2 (ru)
KR (1) KR101666517B1 (ru)
CN (1) CN102171202B (ru)
AU (1) AU2009300869B2 (ru)
BR (1) BRPI0920847A2 (ru)
CA (1) CA2739527C (ru)
EA (1) EA021828B1 (ru)
GB (1) GB0818241D0 (ru)
IL (1) IL211825A (ru)
MX (1) MX2011003697A (ru)
WO (1) WO2010041054A1 (ru)
ZA (1) ZA201102520B (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102558173B (zh) * 2010-12-31 2015-05-20 广州源生医药科技有限公司 抑制wnt信号传导的化合物、组合物及其应用
CN104530042B (zh) * 2010-12-31 2017-11-07 广州源生医药科技有限公司 抑制wnt信号传导的化合物、组合物及其应用
KR101376338B1 (ko) * 2011-09-06 2014-03-19 재단법인 제이씨비 공동생물과학연구소 스타틴계 약물 및 윈트 신호 전달 조절제를 유효성분으로 함유하는 동맥경화증 및 뇌졸중의 예방 또는 치료용 약학 조성물
AU2013212175B2 (en) * 2012-01-28 2017-03-02 Cancer Research Technology Limited Azaheterocyclic compounds
WO2014007228A1 (ja) * 2012-07-03 2014-01-09 小野薬品工業株式会社 ソマトスタチン受容体作動活性を有する化合物およびその医薬用途
ES2698960T3 (es) 2012-10-08 2019-02-06 Merck Patent Gmbh Compuestos de 2-aminopiridina
WO2014086453A1 (en) * 2012-12-07 2014-06-12 Merck Patent Gmbh Azaheterobicyclic compounds
CN103435555B (zh) * 2013-08-27 2015-06-24 贵州威顿晶磷电子材料股份有限公司 一种4-氯-5-甲基嘧啶的制备方法
PL3053916T3 (pl) 2013-09-30 2019-06-28 Ono Pharmaceutical Co., Ltd. Związek mający aktywność agonistyczną wobec receptora somatostatyny i jego farmaceutyczne zastosowanie
WO2015144290A1 (en) * 2014-03-27 2015-10-01 Merck Patent Gmbh Pyridyl piperidines
CN107759584B (zh) * 2016-08-16 2021-06-01 苏州云轩医药科技有限公司 一种具有Wnt信号通路抑制活性的氨基五元杂环化合物及其应用
KR20180061363A (ko) * 2015-10-08 2018-06-07 쑤저우 운씨엔 이야오 커지 요씨엔 공시 Wnt 신호 전달 경로 억제제 및 이의 치료적 적용
JP6967577B2 (ja) * 2016-07-14 2021-11-17 クリネティックス ファーマシューティカルズ，インク． ソマトスタチンモジュレーターとその使用
KR20190121404A (ko) 2017-03-16 2019-10-25 크리네틱스 파마슈티칼스, 인크. 소마토스타틴 조절제 및 이의 용도
EP3658560A4 (en) 2017-07-25 2021-01-06 Crinetics Pharmaceuticals, Inc. SOMATOSTAT IN MODULATORS AND USES THEREOF
CN111868049B (zh) 2018-01-17 2023-06-30 克林提克斯医药股份有限公司 制备促生长素抑制素调节剂的方法
JP7365347B2 (ja) 2018-02-12 2023-10-19 クリネティックス ファーマシューティカルズ，インク． ソマトスタチンモジュレーターおよびその使用
WO2020061046A1 (en) 2018-09-18 2020-03-26 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
WO2020123670A1 (en) * 2018-12-11 2020-06-18 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of the androgen receptor activity and/or expression and uses thereof
TW202115008A (zh) 2019-08-14 2021-04-16 美商克林提克斯醫藥股份有限公司 非肽生長抑制素(somatostatin)5型受體激動劑及其用途
KR20230066379A (ko) 2020-09-09 2023-05-15 크리네틱스 파마슈티칼스, 인크. 소마토스타틴 조절제 제형
CN112707888A (zh) * 2021-02-03 2021-04-27 上海雅本化学有限公司 一种n-2-吡啶基5-嘧啶甲胺的合成方法
US11773076B2 (en) 2021-02-17 2023-10-03 Crinetics Pharmaceuticals, Inc. Crystalline forms of a somatostatin modulator

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8603120D0 (en) * 1986-02-07 1986-03-12 Pfizer Ltd Anti-dysrhythmia agents
GB8609630D0 (en) * 1986-04-19 1986-05-21 Pfizer Ltd Anti-arrhythmia agents
GB9516709D0 (en) 1995-08-15 1995-10-18 Zeneca Ltd Medicament
US6093718A (en) 1996-08-14 2000-07-25 Zeneca Limited Substituted pyrimidine derivatives and their pharmaceutical use
WO1998035956A1 (en) 1997-02-13 1998-08-20 Zeneca Limited Heterocyclic compounds useful as oxido-squalene cyclase inhibitors
CN1311771A (zh) * 1998-06-08 2001-09-05 味之素株式会社 苯甲脒衍生物
DE19920936A1 (de) * 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
US6887870B1 (en) * 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
AU2002221080A1 (en) * 2000-12-08 2002-06-18 Masami Kusaka Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparingthe same and use thereof
WO2004083235A2 (en) 2003-03-19 2004-09-30 Exelixis Inc. Tie-2 modulators and methods of use
AU2004286836A1 (en) 2003-10-28 2005-05-19 Amgen Inc. Triazole compounds and uses related thereto
EP1697375A2 (en) 2003-12-02 2006-09-06 Vertex Pharmaceuticals Incorporated Heterocyclic protein kinase inhibitors and uses thereof
US7354938B2 (en) 2004-03-23 2008-04-08 Amgen Inc. Pyrazole compounds and uses related thereto
AU2005244104B2 (en) * 2004-05-08 2012-03-15 Novartis International Pharmaceutical Ltd. 4,5-disubstituted-2-aryl pyrimidines
CA2585797C (en) * 2004-11-10 2015-01-06 Incyte Corporation Lactam compounds and their use as pharmaceuticals
US20080200431A1 (en) 2005-07-08 2008-08-21 Astrazeneca Ab Heterocyclic Sulfonamide Derivatives as Inhibitors of Factor Xa
AR057965A1 (es) * 2005-12-05 2007-12-26 Incyte Corp Compuestos de lactama y metodos de uso de los mismos
GB0525083D0 (en) * 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
WO2007076055A2 (en) * 2005-12-22 2007-07-05 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
CA2637631C (en) * 2006-01-19 2014-04-29 Orchid Research Laboratories Limited Pyrimidine compounds and uses thereof
RU2008132333A (ru) 2006-02-07 2010-03-20 Вайет (Us) Ингибиторы 11-бета hsd1
MX2008013400A (es) 2006-04-19 2008-11-10 Astellas Pharma Inc Derivado de azolcarboxamida.
WO2007135427A1 (en) 2006-05-23 2007-11-29 Astrazeneca Ab 1,4-disubstituted piperazine and 1,4-disubstituted azepane as 11 -beta-hydroxysteroid dehydrogenase 1 inhibitors
AR064572A1 (es) * 2006-12-28 2009-04-08 Basf Ag Derivados de piridina 2-sustituidas, una composicion farmaceutica que las comprende y su uso en la preparacion de un medicamento para el tratamiento del cancer.

Also Published As

Publication number Publication date
AU2009300869B2 (en) 2014-11-20
KR101666517B1 (ko) 2016-10-14
BRPI0920847A2 (pt) 2015-12-22
JP5711129B2 (ja) 2015-04-30
CA2739527C (en) 2016-08-30
AU2009300869A1 (en) 2010-04-15
KR20110118611A (ko) 2011-10-31
IL211825A0 (en) 2011-06-30
CN102171202A (zh) 2011-08-31
US20110190297A1 (en) 2011-08-04
MX2011003697A (es) 2011-11-18
GB0818241D0 (en) 2008-11-12
EP2331523A1 (en) 2011-06-15
US8778925B2 (en) 2014-07-15
WO2010041054A1 (en) 2010-04-15
IL211825A (en) 2016-08-31
US20140350015A1 (en) 2014-11-27
CA2739527A1 (en) 2010-04-15
JP2012504592A (ja) 2012-02-23
ZA201102520B (en) 2013-09-25
EA021828B1 (ru) 2015-09-30
CN102171202B (zh) 2015-01-07

Similar Documents

Publication Publication Date Title
EA201170531A1 (ru) Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака
EA201390609A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
EA201200473A1 (ru) Замещенные (гетероарилметил)тиогидантоины
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
UA111272C2 (uk) Конденсовані піримідинові похідні для інгібування тирозинкіназної активності
MX2009006706A (es) Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
UA107783C2 (en) Isoindoline compounds for use in treating cancer
EA201500362A1 (ru) Ингибиторы rho-киназы
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
PH12014502772A1 (en) Substituted tricyclic compounds as fgfr inhibitors
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
EA201190158A1 (ru) Производные бензофуранила для применения в качестве ингибиторов глюкокиназы
ATE530540T1 (de) Pyrimidonverbindungen als gsk-3-inhibitoren
EA201170832A1 (ru) Пуриновые соединения
IN2014KN02601A (ru)
EA201270215A1 (ru) Apaf-1 ингибиторные соединения
EA201291143A1 (ru) Пиразолилхиназолиновые ингибиторы киназы
MA32508B1 (fr) Composes organiques
EA200870415A1 (ru) Хиназолины для ингибирования pdk 1
EA201300684A1 (ru) Производные 6-амино-2-фениламино-1н-бензимидазол-5-карбоксамида и их применение в качестве ингибиторов микросомной простагландин-е2-синтазы-1
EA200900798A1 (ru) Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы
EA200900819A1 (ru) Хиназолины для ингибирования pdk1
EA201290184A1 (ru) Бензодиазепиновый ингибитор бромодомена
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
EA201101650A1 (ru) Новые производные пиримидина и их применение в лечении злокачественных новообразований и последующих заболеваний

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ MD TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY KZ KG TJ RU